Skip to main content

Sirolimus protein-bound Side Effects

Medically reviewed by Last updated on Mar 8, 2023.

Applies to sirolimus protein-bound: intravenous powder for suspension.

Serious side effects

Along with its needed effects, sirolimus protein-bound may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking sirolimus protein-bound:

More common

Other side effects

Some side effects of sirolimus protein-bound may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to sirolimus protein-bound: intravenous powder for injection.


The most common adverse reactions were stomatitis (79%), fatigue and rash (68% each), infection (59%), nausea and edema (50% each), and diarrhea, musculoskeletal pain, and decreased weight (47% each).[Ref]


Very common (10% or more): Hypertension (29%)[Ref]


Very common (10% or more): Rash (68%), alopecia (24%), pruritus (18%)

Dry skin (12%), nail disorder (12%)[Ref]


Very common (10% or more): Stomatitis (79%), nausea (50%), diarrhea (47%), vomiting (32%), abdominal pain (29%), constipation (24%), dry mouth (15%), hemorrhoids (12%)[Ref]


Very common (10% or more): Hemorrhage (24%)[Ref]


Very common (10% or more): Decreased appetite (444%), dehydration (15%)[Ref]


Very common (10% or more): Musculoskeletal pain - including arthralgias, back pain, myalgias (47%)[Ref]


Very common (10% or more): Blurred vision (12%)[Ref]


Very common (10% or more): Infections - upper respiratory tract infection, urinary tract infection, sinusitis, skin infection, folliculitis, nasopharyngitis, pharyngitis, pharyngitis streptococcal, pneumonia, vaginal infection (59%)[Ref]


Very common (10% or more): Insomnia (21%)[Ref]


Very common (10% or more): Cough (35%), pneumonitis (18%), dyspnea (12%)[Ref]


1. Product Information. Fyarro (sirolimus protein-bound). Aadi Bioscience, Inc. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.